Journal of Capital Medical University ›› 2004, Vol. 25 ›› Issue (2): 223-226.

• 论著·临床研究 • Previous Articles     Next Articles

4G/5G Polymorphism at Plasminogen Activator Inhibitor-1 Promoter in Patients with Type Ⅱ Diabetic and Coronary Artery Disease

Wang Xudong1, Fan Zheng2, Fu Yan1, Yin Hong2, Zhai Yanling3, Qi Yahui2, Zhu Yuqing1, Wang Jin1, Zhao Xiangyin3   

  1. 1. Department of Emergency, Beijing Tongren Hospital, Affiliate of Capital University of Medical Sciences;2. Experimental Center, Capital University of Medical Science;3. Department of Hematology, Beijing Tongren Hospital
  • Received:2003-04-21 Revised:1900-01-01 Online:2004-04-15 Published:2004-04-15

PDF

217

Abstract: The aim was to investigate the genotype at a plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism in patients with type Ⅱ diabetes and complicated coronary artery disease(CAD). The level of PAI-1 antigen was measured and the 4G/5G polymorphism genotype was determined by polymerase chain reaction(PCR) amplification of genomic DNA using the allele specific primers in Chinese type Ⅱ diabetes subjects(121 type Ⅱ diabetes patients, 87 diabetic patients with CAD) and 100 control subjects. The frequency of the 4G/4G genotype increased and that of the 5G/5G genotype decreased in group of diabetic CAD compared with control subjects(49.4% vs. 37.0%, P< 0.05). The level of PAI-1 antigen was positively correlated with levels of triglyceride(P<0.001) and associated with 4G/5G polymorphism (P=0.03). PAI-1 antigen level was significantly higher in 4G/4G genotype carriers than in 5G/5G genotype carriers in group of CAD 〔(39.82×10-3 ±3.11×10-3)ng/L vs (38.04× 10-3±2.73×10-3)ng/L, P<0.05〕. This polymorphic variation at PAI-1 promoter interacts with risk factors of triglyceride when associated with increased level of PAI-1 antigen and pathogenesis of CAD in type Ⅱ diabetes.

Key words: plasminogen activator inhibitor-1, gene polymorphism, type Ⅱ diabetes, coronary artery disease

CLC Number: